摘要
【目的】观察低分子肝素治疗高原红细胞增多症（HAPC）的临床疗效。【方法】将60例HAPC患者随机分为治疗组与对照组各30倒。对照组给予常规治疗（呼吸功能锻炼、间歇吸氧流量1～2L／min，每次1～2h，2～3次／日、红景天600mg，2次／日，15d一疗程）。治疗组在常规治疗的基础上加用低分子肝素5000IU腹壁皮下注射，12h1次，10～14d为1疗程，比较两组疗效。【结果】治疗组：显效22例，有效7例，无效1例，总有效率96．7％；对照组：显效10例，有效5例，无效15例，总有效率50％。治疗组总有效率明显高于对照组，且两组相比较差异有显著性（P〈0．05）。【结论】低分子肝素治疗HAPC安全有效。
[Objective] To observe the clinical efficacy of low molecular heparin for the treatment of patients with high altitude polycythernia（HAPC）. [Methods] A total of 60 HAPC patients were randomly divided into treatment group （n=30） and control group（ n=30）. The control group was given routine treatment（respiratory function exercise, intermittent oxygen flow with 1-2 L/min once per 1-2 h and twice or three time a day, and Hongiingtian 600rag twice a day for a course of 15d）. The treatment group was treated with routine therapy plus abdominal subcutaneous injection of low molecular weight heparin 5000 IU once per 12h for a course of 10-14d. The efficacy was compared between 2 groups. [Results]In the treatment group, 22 patients were excellent, and 7 patients were effective, and 1 patient was ineffective, and the total effective rate was 96.7%. In the control group, 10 patients were excellent, and 5 patients were effective, and 15 patients were ineffective, and the total effective rate was 50%. The total effective rate in treatment group was obviously higher than that in control group, and there was significant difference between 2 groups（ P d0. 05）. [Conclusion] Low molecular heparin for the treatment of HAPC is safe and effective.
出处
《医学临床研究》
CAS
2012年第10期1874-1875,共2页
Journal of Clinical Research
